DV
Dividend Vision

IKT — Inhibikase Therapeutics Inc

Inhibikase Therapeutics Inc (IKT)

Total return is -95.9% over the past 5.6 years, 223.4 points behind SPY at 127.5%. Its deepest 1-year drawdown was 26.8%.

Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing therapeutics for cardiopulmonary diseases, with a focus on pulmonary arterial hypertension (PAH). Its lead candidate, IKT-001, is an oral prodrug of imatinib designed to treat PAH while potentially reducing gastrointestinal side effects; the company is currently evaluating this treatment in a global Phase 3 clinical trial. The company does not currently distribute dividends and is typical of early-stage biotech firms, appealing primarily to investors with risk tolerance for clinical-stage drug development and potential capital appreciation rather than income generation.

IKT key facts

Asset type
Stock
Asset class
Equity
Inception date
12/23/2020
Last close
$2.41
Market cap
$350,182,784
Average volume
227900.0
Beta
0.943
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.46